Re: A vs V
in response to
by
posted on
Mar 29, 2019 09:07PM
The "problem" here is that no one knows how Vascepa works. So no one would know whether or not they'd be complementary until a specific Phase 3 were to be run, right?
Anyway, it seems to me that A is more a threat to V than the other way around. If that's the case, the owners of AMRN stock should be concerned....